Effectiveness of mRNA-based vaccines during the emergence of SARS-CoV-2 Omicron variant

Aditya Sharma MD*, Gina Oda MS1, Mark Holodniy MD1,2

1US Department of Veterans Affairs, Public Health Program, Washington, DC and Palo Alto, CA, USA
2Stanford University, Stanford, CA, USA

*Corresponding Author          Alternate Corresponding Author
Aditya Sharma MD          Mark Holodniy MD
aditya.sharma@va.gov       mark.holodniy@va.gov
US Department of Veterans Affairs          US Department of Veterans Affairs
Public Health Program          Public Health Program
Palo Alto, CA 94304 USA          Palo Alto, CA 94304 USA

Running Title
Vaccine effectiveness against Omicron
Abstract

Background
We evaluated effectiveness of mRNA-based vaccines following emergence of SARS-CoV-2 Omicron variant.

Methods
Recipients of a third dose of BNT162b2 or mRNA-1273 ≥ 180 days after the primary series were matched to primary series recipients and unvaccinated persons. Participants were followed from December 1, 2021 to March 12, 2022. Outcomes were documented SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 death. Effectiveness was calculated from 100-day risks estimated with the Kaplan-Meier estimator.

Results
BNT162b2 and mRNA-1273 groups respectively included 221,267 and 187,507 third dose recipients matched to equal numbers of primary series recipients and unvaccinated persons. Compared to no vaccination, effectiveness of a third dose of BNT162b2 was 47.8% (95% confidence interval [CI]: 45.2-50.3), 81.8% (95% CI 79.2-84.2), and 89.6% (95% CI 85.0-93.6) against documented infection, hospitalization, and death, respectively. Effectiveness of a third dose of BNT162b2 compared to the primary series was 30.1% (95% CI 26.2-33.7), 61.4% (95% CI 55.0-67.1), and 78.8% (95% CI 67.9-87.5) against documented infection, hospitalization, and death, respectively.

Effectiveness of a third dose of mRNA-1273 compared to no vaccination was 61.9% (95% CI 59.4-64.4), 87.9% (95% CI 85.3-90.2), and 91.4% (95% CI 86.4-95.6) against documented infection, hospitalization, and death, respectively. Effectiveness of a third dose of mRNA-1273 compared to the primary series was 37.1% (95% CI 32.2-41.7), 63.5% (95% CI 53.7-71.6), and 75.0% (95% CI 55.4-88.0) against documented infection, hospitalization, and death, respectively.

Conclusions
BNT162b2 and mRNA-1273 were effective against COVID-19 following emergence of Omicron variant. A third dose provided additional protection over the primary series.

Keywords
COVID-19, epidemiology, vaccine, Omicron
Background

Messenger RNA (mRNA) based vaccines have demonstrated significant protection against COVID-19 compared to unvaccinated persons in clinical as well as in observational studies [1-4]. The spread of the SARS-CoV-2 delta variant, resurgence of COVID-19 infections, and concern about waning antibody levels among vaccinated persons led US Food and Drug Administration (FDA) to authorize a third dose of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) 6 months after completing the primary series for vaccinated persons at high risk of severe disease or exposure to COVID-19 [5, 6]. Soon after, several states expanded eligibility of booster doses to all adults as part of a continued effort to control COVID-19 [7-9]. On November 19, 2021 FDA expanded eligibility for booster vaccine doses to all individuals 18 years and older after completing the primary vaccine series [10]; eligibility was adjusted to everyone 12 years and older for recipients of BNT162b2 [11]. By April 1, 2022, US Centers for Disease Control and Prevention (CDC) estimated that more than 65% of the US population was fully vaccinated, and 45% of fully vaccinated persons had received an additional dose of vaccine [12].

The emergence and rapid dissemination of the SARS-CoV-2 Omicron variant in December 2021 raised new questions about the effectiveness of mRNA-based vaccines against this novel strain. Early reports from South Africa and the US CDC suggest protection against Omicron variant, though these studies were limited to hospitalized individuals [13, 14]. Additional studies in frontline healthcare workers and for self-reported symptomatic COVID-19 following the emergence of Omicron variant have indicated continued effectiveness of mRNA-based vaccines [15, 16]. The effectiveness of mRNA-based vaccines across the clinical spectrum of COVID-19 severity, as well as the effectiveness of completing the primary series of two doses...
in contrast to receiving a third dose has yet to be assessed. Observational studies in Israel demonstrated effectiveness of a third dose of BNT162b2 in preventing post-vaccination COVID-19 compared to persons who only completed the primary series [17, 18]. However, these studies predated the emergence of Omicron variant; vaccine effectiveness of mRNA-based vaccines in the era of Omicron variant predominance has yet to be fully evaluated in the United States.

We leveraged electronic health records from the Veterans Health Administration (VHA), to estimate the effectiveness of BNT162b2 and mRNA-1273 vaccines in preventing post-vaccination COVID-19 infection following the emergence of Omicron variant.

**Methods**

VHA is the largest integrated health system in the United States, providing healthcare services at 1,293 facilities [19]. Individual-level clinical records are parsed and imported into the VHA Corporate Data Warehouse, which is used to conduct observational studies as well as to monitor multi-level operations. VHA implemented vaccination for COVID-19 beginning in December 2020. The study period was December 1, 2021 to March 12, 2022. For study inclusion, an individual needed to have had at least one primary care visit in a VHA facility during calendar year 2020, and not have had a documented positive SARS-CoV-2 PCR test before December 1, 2021. Individuals who received a dose of Ad26.COV2.S, who received doses of both BNT162b2 and mRNA-1273, or who were admitted to long-term care facilities were excluded. Three subgroups were considered: persons with no documented administration of an mRNA-based vaccine (unvaccinated persons), individuals who had received two doses of BNT162b2 or mRNA-1273 before December 1, 2021 (primary series recipients), and persons who received an additional dose of BNT162b2 or mRNA-1273 after completing the primary series at least 14 days before December 1, 2021 (third dose recipients).
For each vaccine type, third dose recipients were matched with equal numbers of primary series recipients and unvaccinated persons on multiple demographic and clinical covariates: age, sex, race/ethnicity, comorbidities (summarized by the Elixhauser comorbidity score [20, 21]), and US county of residence. Third dose recipients and primary series recipients were matched on an additional covariate corresponding to the calendar week in which the second dose of vaccine was received. To account for healthcare seeking behavior, subgroups were also matched on number of SARS-CoV-2 PCR tests received before the study start date.

Three outcomes were considered: documented SARS-CoV-2 infection (defined as a positive SARS-CoV-2 PCR test) and COVID-19 hospitalization (defined as documented SARS-CoV-2 infection within 21 days before admission to an inpatient unit in an acute care VHA facility), and COVID-19 death (defined as death within 30 days after documented SARS-CoV-2 infection). For each outcome and vaccine, individuals were followed from recruitment until the earliest date of outcome, death, or end of the study period. Follow up of primary series recipients was also halted if a third vaccine dose was received during follow up.

The Kaplan-Meier estimator was used to calculate the 100-day cumulative incidence (risk) of outcomes for each subgroup and vaccine. Vaccine effectiveness ($1 - \text{risk ratio}$) was calculated for three measures: primary series compared to unvaccinated, third dose compared to unvaccinated, and primary series compared to third dose. Non-parametric bootstrapping with 1,000 samples was used to calculate 95% confidence intervals. All analyses were performed in R version 4.10 [22].

This project was approved by the Stanford University Institutional Review Board (Protocol ID 47191, “Public Health Surveillance in the Department of Veterans Affairs”) and written informed consent was waived.
Results

At the study start date, 1,237,990 individuals who received BNT162b2 and 1,404,183 persons vaccinated with mRNA-1273 met eligibility criteria. Among these, 366,293 (29.6%) and 309,050 (22.0%) individuals received a third dose of BNT162b2 or mRNA-1273, respectively. Additionally, by December 1, 2021, 1,821,245 individuals were unvaccinated. After matching, the BNT162b2 group consisted of 221,267 third dose recipients and the mRNA-1273 group included 187,507 third dose recipients linked to equal numbers of unvaccinated and primary series recipients who had not received a third dose. Baseline demographic characteristics were similar across matched populations within vaccine groups (Table 1). Participants were older persons, mostly male, and non-Hispanic White. Most (>80%) participants did not undergo SARS-CoV-2 PCR testing before the start of follow up. About a quarter of study participants in each group had an Elixhauser comorbidity score of 10 or greater. Among vaccinated participants, more than 50% had completed the primary series at least 250 days before the study start date. The median time that had elapsed from receipt of the third dose before start of follow up was 48 days for the BNT162b2 group and 28 days for the mRNA-1273 group.

In both vaccine groups, documented SARS-CoV-2, COVID-19 hospitalization, and COVID-19 death occurred more frequently in unvaccinated persons compared to those who completed the primary series or received a third dose (Table 1; Figures 1, 2, 3). In the analysis of BNT162b2, the 100-day cumulative incidence of documented SARS-CoV-2 infection was 2.44% (95% confidence interval [CI] 2.37-2.50) in unvaccinated, 1.82% (95% CI 1.76-1.89) in primary series recipients, and 1.27% (95% CI 1.23-1.32) in third dose recipients. The 100-day cumulative incidence of COVID-19 hospitalization in the BNT162b2 group was 0.67% (95% CI 0.63-0.70) in unvaccinated, 0.31% (95% CI 0.29-0.34) in primary series recipients, and 0.12% (95% CI
0.11-0.14) in third dose recipients. The 100-day risk of COVID-19 death in the BNT162b2 group was 0.13% (95% CI 0.11-0.14) in unvaccinated, 0.061% (95% CI 0.050-0.073) in primary series recipients, and 0.013% (95% CI 0.008-0.018) in third dose recipients.

The findings in the mRNA-1273 analysis were similar: 100-day cumulative incidence of documented SARS-CoV-2 infection was 1.99% (95% CI 1.93-2.06) in unvaccinated, 1.21% (95% CI 1.15-1.26) in primary series recipients, and 0.76% (95% CI 0.72-0.80) in third dose recipients; cumulative incidence of COVID-19 hospitalization was 0.49% (95% CI 0.45-0.52) in unvaccinated, 0.16% (95% CI 0.14-0.18) in primary series recipients, and 0.059% (95% CI 0.048-0.070) in third dose recipients. The 100-day risk of COVID-19 death was 0.093% (95% CI 0.079-0.107) in unvaccinated persons, 0.032% (95% CI 0.023-0.041) in primary series recipients, and 0.008% (95% CI 0.004-0.012) in third dose recipients.

Compared to no vaccination, estimated effectiveness of BNT162b2 against documented SARS-CoV-2 infection was 47.8% (95% CI 45.2-50.3) for a third dose and 25.3% (95% CI 21.8-28.7) for the primary series; against COVID-19 hospitalization was 81.8% (95% CI 79.2-84.2) for a third dose and 52.9% (47.8-57.6) for the primary series; and against COVID-19 death was 89.6% (95% CI 85.0-93.6) for a third dose and 50.7% (95% CI 37.9-61.6) for the primary series (Table 2). A third dose of BNT162b2 compared to the primary series was 30.1% (95% CI 26.2-33.7), 61.4% (95% CI 55.0-67.1), and 78.8% (95% CI 67.9-87.5) effective against documented SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 death, respectively.

Estimated effectiveness of a third dose of mRNA-1273 compared to no vaccination was 61.9% (95% CI 59.4-64.4) for documented SARS-CoV-2 infection, 87.9% (95% CI 85.3-90.2) for COVID-19 hospitalization, and 91.4% (95% CI 86.4-95.6) for COVID-19 death (Table 2).
Effectiveness of the primary series compared to no vaccination was 39.5% (95% CI 35.8-43.0) for documented SARS-CoV-2 infection, 66.7% (95% CI 61.4-71.6) for COVID-19 hospitalization, and 65.6% (95% CI 52.8-76.3) for COVID-19 death. Compared to the primary series, a third dose of mRNA-1273 was 37.1% (95% CI 32.2-41.7), 63.5% (95% CI 53.7-71.6), and 75.0% (95% CI 55.4-88.0) effective against documented SARS-CoV2-infection, COVID-19 hospitalization, and COVID-19 death, respectively.

**Discussion**

National surveillance of SARS-CoV-2 variants indicates that the Omicron has exceeded more than 90% of the weekly proportion of variants since January 2022, and more than 99% since February 2022, heralding the era of Omicron variant predominance [23]. We estimated the effectiveness of BNT162b2 and mRNA-1273 vaccines following the emergence and spread of SARS-CoV-2 Omicron variant in the largest healthcare system in the United States, and demonstrated substantial protective effect of mRNA-based vaccines against severe post-vaccination COVID-19 infections during this new era. Compared to no vaccination, a third dose was more than 80% effective against COVID-19 hospitalization and death. Protective effects were also observed for documented SARS-CoV-2 infection, though with lower estimates than for COVID-19 hospitalization or death. A third dose of vaccine demonstrated higher effectiveness against both outcomes compared to the primary series. Our findings of effectiveness of mRNA-based against COVID-19 during the Omicron surge are comparable to recent reports in South Africa [24] and in the United States [13, 15, 16]. Our study expands on these reports by estimating effectiveness across the clinical spectrum of post-vaccination COVID-19 infections for both BNT162b2 and mRNA-1273 vaccines as well as demonstrating added protection of a third dose compared to the primary series.
We observed that all measured COVID-19 infection outcomes occurred less frequently in persons who received the third dose of vaccine compared to individuals who completed the primary series. These observations are consistent with differences in predicted pathways of vaccine-mediated immunity against Omicron variant: heightened antibody evasion facilitates mild illness, but an unimpaired cellular immune response maintains protection against severe infection [14, 25-27]. Reduced frequency of outcomes in persons who received a third dose compared to the primary series might be explained by restored antibody levels that would otherwise have been reduced after completing the primary series. However, our observations might be explained by differences in exposures: those sufficiently concerned about post-vaccination infection to seek an additional vaccine dose might also choose less risky behaviors than non-recipients; therefore, differences in general preventive behaviors between third dose recipients and non-recipients might confound the frequency of observed outcomes. Similarly, older persons or those with higher number of comorbidities might not engage in as many social activities compared to younger, healthier individuals, and consequently might not experience comparable transmission risk. Our study also suggests longitudinal protection of the primary series of mRNA-based vaccines against severe COVID-19 infection, with COVID-19 hospitalization occurring in less than 0.4% and COVID-19 death occurring in less than 0.1% of primary series recipients of BNT162b2 or mRNA-1273 in 100 days of observation following emergence of Omicron variant.

Though we observed considerable protection of mRNA-based vaccines against COVID-19 infection, it is unclear whether this improvement affects broader efforts to reduce COVID-19 transmission. Early studies in the United Kingdom demonstrated that household contacts of vaccinated cases had lower risk of symptomatic secondary infection compared to household
contacts of unvaccinated cases [28]. However, after the emergence of delta variant, the protective
effect on household contacts was less clear: a large observational study in the United Kingdom
demonstrated that vaccinated persons carry similar peak viral loads as unvaccinated persons but
for a shorter duration; additionally, the secondary attack rate among household contacts did not
differ by vaccination status of the index case, and transmission was observed to occur among
fully vaccinated index case-contact pairs [29]. The heightened evasion to neutralizing antibodies
coupled with evidence of rapid spread globally suggests that transmission of Omicron variant
might not be substantially affected by previous immunity or vaccination. At the population level,
it is likely that a third dose of mRNA-based vaccines will remain important in preventing severe
infection, particularly among high-risk individuals; the effect on curtailing transmission is less
certain and warrants further study.

Our findings are subject to several limitations. Clinical records for patients who received
care in facilities external to VHA might not be available in VHA databases unless these services
were ordered by VHA providers and paid for by VHA; therefore, these testing episodes and
outcomes would be missed in our analysis. Although VHA issued national testing guidelines,
differences across VHA facilities in testing assays and local policies or approaches to testing
may contribute to variability in detection of vaccine breakthrough events; some events might
have been missed or misclassified. Our study population consists of predominantly older
(median age 75 years), male persons (98%) receiving care at VHA facilities; therefore, our
results might not be generalizable to the larger US population. Positive PCR tests in hospitalized
persons and decedents may be incidental findings not associated with severe COVID-19
infection; misclassification might affect the accuracy of our estimates for these outcomes.

Though we sought to control for health-seeking behavior as well as demographic and clinical
covariates associated with COVID-19, unmeasured confounders might affect our findings. To reduce residual confounding, we excluded long term care residents; our findings might not be applicable to this subgroup. To focus on recent users of VHA services, we selected eligible persons as those who received a primary care visit in 2020; vaccine effectiveness among irregular users of VHA services and those who enrolled after 2021 might differ compared to our estimates. We excluded persons with a documented positive SARS-CoV-2 PCR test before December 2021; our estimates of vaccine effectiveness thereby exclude the effects of infection-induced immunity, though it is possible that some enrolled individuals might have had previously undiagnosed or undocumented COVID-19 infection. Though VHA performs passive surveillance of SARS-CoV-2 variants, confirmation of the causative variant for each outcome was not possible; however, both internal VHA genomic surveillance data (unpublished data) as well as variants proportions reported by CDC confirm the predominance of Omicron variant during the study period [23]. We did not generate estimates during periods of predominance of other variants, though unobserved, temporally-associated variables would adversely affect the accuracy of comparative effectiveness across variant-specific periods. Given the observational nature of this study, data describing additional biomarkers, timing of exposures, symptoms, and the specific variants occurring in vaccine breakthrough events were unavailable; therefore, we were unable to assess the importance of these factors with post-vaccination infection.

In summary, we observed substantial effectiveness of BNT162b2 and mRNA-1273 against measured COVID-19 infection outcomes following the emergence of Omicron variant. Compared to unvaccinated individuals, those who received a third dose or who completed the primary series experienced fewer episodes of documented SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 death; a third dose was more effective than the primary series for
most outcomes. Clinicians and public health administrators should consider these findings in the broader context of patient- and population-level efforts to combat COVID-19 in this new chapter of the pandemic.

NOTES

Contributions

Conceptualization: AS, GO, MH

Data curation: AS

Formal analysis: AS

Methodology: AS

Project administration: AS, GO, MH

Resources: AS, GO, MH

Software: AS

Supervision: MH

Visualization: AS

Writing (original draft): AS

Writing (review & editing): AS, GO, MH

Data sharing: Due to US Department of Veterans Affairs (VA) regulations, the analytic datasets used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is consistent with other studies based on VA data.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

Funding: None.

Conflicts of Interest: None.
References

1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384(5): 403-16.
2. Haas EH, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397(10287): 1819-29.
3. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021; 385(7): 585-94.
4. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine for Certain Populations. Available at: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations. Accessed October 29, 2021.
5. US Food and Drug Administration. FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines. Accessed October 20, 2021.
6. US Food and Drug Administration. FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines. Accessed October 20, 2021.
7. Colorado Department of Public Health & Environment. Find out if you need a COVID-19 vaccine booster. Available at: https://covid19.colorado.gov/vaccine-booster-eligibility. Accessed November 15, 2021.
8. California Department of Public Health. Booster messaging. Available at: https://eziz.org/assets/docs/COVID19/CDPHBoosterLetter.LHJsandProviders.pdf. Accessed November 9, 2021.
9. New Mexico Office of the Governor. State extends booster eligibility to all New Mexico adults. Available at: https://www.governor.state.nm.us/2021/11/12/state-extends-booster-eligibility-to-all-new-mexico-adults/. Accessed November 12, 2021.
10. US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters. Accessed November 19, 2021.
11. US Food and Drug Administration. FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine. Available at: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations. Accessed March 31, 2022.
12. US Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Available at: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total. Accessed February 2, 2022.
13. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 139-45.
14. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022.
1. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 2022; 327(7): 639-51.
2. Yoon SK, Hegmann KT, Thiese MS, et al. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med 2022.
3. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med 2021; 385(15): 1393-400.
4. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021.
5. US Department of Veterans Affairs. Veterans Health Administration. Available at: https://www.va.gov/health/. Accessed November 15, 2021.
6. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009; 47(6): 626-33.
7. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36(1): 8-27.
8. R Core Team. R: A language and environment for statistical computing, R Foundation for Statistical Computing. Vienna, Austria. 2021.
9. US Centers for Disease Control and Prevention. COVID Data Tracker: Variant Proportions. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed October 1, 2021.
10. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 2021.
11. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2021.
12. Lu L, Mok BW, Chen LL, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis 2021.
13. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021.
14. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med 2021; 385(8): 759-60.
15. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 2021.
Table 1. Characteristics and outcomes of study participants in BNT162b2 and mRNA-1273 groups stratified by vaccination status.

| Characteristic                          | BNT162b2                | mRNA-1273               |
|-----------------------------------------|-------------------------|-------------------------|
|                                         | Third dose N = 221,267  | Primary series N = 221,267 | Unvaccinated N = 221,267 | Third dose N = 187,507 | Primary series N = 187,507 | Unvaccinated N = 187,507 |
| Age (years)†                            | 74 (69, 77)             | 74 (69, 77)             | 73 (68, 77)             | 75 (71, 79)              | 75 (71, 79)              | 74 (70, 79)              |
| Sex                                     |                         |                         |                         |                         |                         |                         |
| Female                                  | 5,514 (2.5%)            | 5,514 (2.5%)            | 5,514 (2.5%)            | 2,928 (1.6%)             | 2,928 (1.6%)             | 2,928 (1.6%)             |
| Male                                    | 215,753 (97.5%)         | 215,753 (97.5%)         | 215,753 (97.5%)         | 184,579 (98.4%)          | 184,579 (98.4%)          | 184,579 (98.4%)          |
| Race/Ethnicity                          |                         |                         |                         |                         |                         |                         |
| Hispanic or Latino                      | 8,939 (4.0%)            | 8,939 (4.0%)            | 8,939 (4.0%)            | 8,154 (4.3%)             | 8,154 (4.3%)             | 8,154 (4.3%)             |
| Non-Hispanic Black                      | 42,496 (19.2%)          | 42,496 (19.2%)          | 42,496 (19.2%)          | 20,633 (11.0%)           | 20,633 (11.0%)           | 20,633 (11.0%)           |
| Non-Hispanic White                      | 156,508 (70.7%)         | 156,508 (70.7%)         | 156,508 (70.7%)         | 148,166 (79.0%)          | 148,166 (79.0%)          | 148,166 (79.0%)          |
| Other                                   | 13,324 (6.0%)           | 13,324 (6.0%)           | 13,324 (6.0%)           | 10,554 (5.6%)            | 10,554 (5.6%)            | 10,554 (5.6%)            |
| Elixhauser comorbidity score            |                         |                         |                         |                         |                         |                         |
| < 0                                     | 46,786 (21.1%)          | 46,786 (21.1%)          | 46,786 (21.1%)          | 36,497 (19.5%)           | 36,497 (19.5%)           | 36,497 (19.5%)           |
| 0-4                                     | 82,994 (37.5%)          | 82,994 (37.5%)          | 82,994 (37.5%)          | 70,975 (37.9%)           | 70,975 (37.9%)           | 70,975 (37.9%)           |
| 5-9                                     | 39,506 (17.9%)          | 39,506 (17.9%)          | 39,506 (17.9%)          | 36,404 (19.4%)           | 36,404 (19.4%)           | 36,404 (19.4%)           |
| ≥10                                     | 51,981 (23.5%)          | 51,981 (23.5%)          | 51,981 (23.5%)          | 43,631 (23.3%)           | 43,631 (23.3%)           | 43,631 (23.3%)           |
| Number of previous PCR tests            |                         |                         |                         |                         |                         |                         |
| 0                                       | 179,453 (81.1%)         | 179,453 (81.1%)         | 179,453 (81.1%)         | 160,515 (85.6%)          | 160,515 (85.6%)          | 160,515 (85.6%)          |
| 1                                       | 23,643 (10.7%)          | 23,643 (10.7%)          | 23,643 (10.7%)          | 16,219 (8.6%)            | 16,219 (8.6%)            | 16,219 (8.6%)            |
| 2-3                                     | 13,356 (6.0%)           | 13,356 (6.0%)           | 13,356 (6.0%)           | 8,243 (4.4%)             | 8,243 (4.4%)             | 8,243 (4.4%)             |
| Characteristic                                      | BNT162b2                                                                 | mRNA-1273                                                                  |
|----------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
|                                                    | Third dose       | Primary series | Unvaccinated | Third dose       | Primary series | Unvaccinated |
|                                                    | N = 221,267      | N = 221,267    | N = 221,267  | N = 187,507      | N = 187,507    | N = 187,507  |
| ≥ 4                                                | 4,815 (2.2%)     | 4,815 (2.2%)  | 4,815 (2.2%) | 2,530 (1.3%)     | 2,530 (1.3%)  | 2,530 (1.3%) |
| Time since completion of primary series before     | 279 (258, 289)  | 279 (258, 289) | -            | 268 (257, 285)  | 268 (256, 285) | -            |
| follow-up (days)
| Time since last vaccine dose before follow-up (days)
| 48 (35, 60)  | 279 (258, 289) | -            | 28 (21, 35)  | 268 (256, 285) | -            |
| Outcomes                                          | 2,806 (1.3%)    | 3,506 (1.6%)  | 5,335 (2.4%) | 1,420 (0.8%)    | 1,850 (1.0%)  | 3,697 (2.0%) |
| Documented SARS-CoV-2 Infection                   | 42 (34, 52)     | 36 (28, 48)   | 40 (30, 52)  | 44 (36, 56)     | 40 (30, 52)   | 42 (30, 54)  |
| Time since start of follow-up (days)              | 92 (76, 108)    | 314 (292, 332)| -            | 76 (62, 98)     | 310 (290, 328)| -            |
| Time since last vaccine dose (days)
| COVID-19 Hospitalization                          | 267 (0.1%)     | 598 (0.3%)    | 1,461 (0.7%) | 110 (0.1%)      | 248 (0.1%)    | 900 (0.5%)   |
| Time since start of follow-up (days)
| 50 (36, 64)  | 42 (30, 54)    | 44 (32, 58)   | 54 (41, 68)  | 44 (27, 58)     | 44 (30, 58)   |
| Time since last vaccine dose (days)
| COVID-19 Death                                    | 104 (82, 123)  | 326 (310, 340)| -            | 97 (74, 129)   | 320 (300, 332)| -            |
| Time since start of follow-up (days)
| 29 (<0.1%)  | 113 (0.1%)     | 273 (0.1%)    | 15 (<0.1%)  | 47 (<0.1%)      | 172 (0.1%)    |
| Time since last vaccine dose (days)
| COVID-19 Death                                    | 52 (42, 66)    | 52 (46, 64)   | 56 (38, 70)   | 68 (55, 78)     | 58 (41, 72)   | 56 (38, 64)  |
| Time since start of follow-up (days)
| 108 (98, 132)| 338 (320, 352)| -            | 114 (106, 138)| 328 (318, 350) | -            |

Numbers describe n (%) unless otherwise noted.

1Median (IQR)
Table 2. Estimated effectiveness of BNT162b2 and mRNA-1273 vaccines.

| Outcome                                      | Effectiveness (%) (95% CI) |
|----------------------------------------------|---------------------------|
|                                              | BNT162b2                  | mRNA-1273                 |
| Documented SARS-CoV-2 infection              |                           |                           |
| Third dose: unvaccinated                     | 47.8 (45.2-50.3)          | 61.9 (59.4-64.4)          |
| Primary series: unvaccinated                 | 25.3 (21.8-28.7)          | 39.5 (35.8-43.0)          |
| Third dose: primary series                   | 30.1 (26.2-33.7)          | 37.1 (32.2-41.7)          |
| COVID-19 hospitalization                     |                           |                           |
| Third dose: unvaccinated                     | 81.8 (79.2-84.2)          | 87.9 (85.3-90.2)          |
| Primary series: unvaccinated                 | 52.9 (47.8-57.6)          | 66.7 (61.4-71.6)          |
| Third dose: primary series                   | 61.4 (55.0-67.1)          | 63.5 (53.7-71.6)          |
| COVID-19 death                              |                           |                           |
| Third dose: unvaccinated                     | 89.6 (85.0-93.6)          | 91.4 (86.4-95.6)          |
| Primary series: unvaccinated                 | 50.7 (37.9-61.6)          | 65.6 (52.8-76.3)          |
| Third dose: primary series                   | 78.8 (67.9-87.5)          | 75.0 (55.4-88.0)          |
Figure 1. Cumulative incidence of documented SARS-CoV-2 infection by vaccination status and manufacturer. Shaded areas describe 95% confidence intervals.

Figure 2. Cumulative incidence of COVID-19 hospitalization by vaccination status and manufacturer. Shaded areas describe 95% confidence intervals.

Figure 3. Cumulative incidence of COVID-19 deaths by vaccination status and manufacturer. Shaded areas describe 95% confidence intervals.
Figure 1
254x127 mm (0.5 x DPI)

Figure 2
254x127 mm (0.5 x DPI)
Figure 3
254x127 mm (0.5 x DPI)